New Deal Advisors supports SGD Pharma in the acquisition of Alphial
Milan, August 28, 2025 – New Deal Advisors, an independent firm specializing in advisory services to M&A Transactions, has supported SGD Pharma, a French group active in primary packaging for the pharmaceutical industry controlled by the Pai Partners fund, in the acquisition of the Alphial pharmaceutical group.
For SGD Pharma, the acquisition of Alphial represents a further step in consolidating its European presence, strengthening its tubular glass production.
New Deal Advisors, with a team led by Antonio Ficetti Gasco (partner), who was assisted by Eight International, a global network of which New Deal Advisors is a founding member, provided financial due diligence services to SGD Pharma.
***
New Deal Advisors
New Deal Advisors is an independent firm specialising in advisory services in M&A. Established in 2012, New Deal Advisors provides support in a broad variety of extraordinary transactions streams including mergers and acquisitions, restructuring, transformation processes, forensic and litigation activities, fairness opinions and valuation services. New Deal Advisors has worked for more than a decade alongside private equity funds, investment holdings, family offices, financial institutions and strategic players achieving to date the finalisation of over 200 deals.